JP Morgan Chase’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-17,800
Closed -$584K 7387
2023
Q4
$584K Sell
17,800
-45,000
-72% -$1.22M ﹤0.01% 4686
2023
Q3
$1.75M Buy
62,800
+45,000
+253% +$1.47M ﹤0.01% 3640
2023
Q2
$607K Hold
17,800
﹤0.01% 4377
2023
Q1
$535K Hold
17,800
﹤0.01% 4455
2022
Q4
$502K Buy
+17,800
New +$565K ﹤0.01% 4517

Other funds holding ARKG

JP Morgan Chase's ARKG Position: Q1 2026 in Review

JP Morgan Chase increased its ARK Genomic Revolution ETF (ARKG) stake by 40% in Q1 2026, buying an estimated $61M and bringing the position to 7,230,809 shares worth $179M. The position accounts for 0.01% of the portfolio, ranked #733.

JP Morgan Chase first reported a position in ARKG in Q4 2019 and has held it in 26 quarters since. 218 funds tracked by Wall St. Rank hold ARKG as of Q1 2026.

  • JP Morgan Chase held 7,230,809 shares of ARK Genomic Revolution ETF worth $179M as of Q1 2026.
  • JP Morgan Chase bought 2,081,355 ARK Genomic Revolution ETF shares in Q1 2026, an estimated $61M.
  • ARK Genomic Revolution ETF made up 0.01% of JP Morgan Chase's portfolio in Q1 2026, its #733 holding.
  • JP Morgan Chase first reported a position in ARK Genomic Revolution ETF in Q4 2019 and has held it in 26 quarters since.
  • 218 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.